{"id":"NCT00289718","sponsor":"GlaxoSmithKline","briefTitle":"Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule","officialTitle":"Long-Term Persistence Follow-up Study to Evaluate the Immune Persistence of GSK Biologicals' Combined Hepatitis A / Hepatitis B Vaccine in Healthy Adult Volunteers","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-11-01","primaryCompletion":"2005-03-02","completion":"2005-03-02","firstPosted":"2006-02-10","resultsPosted":"2010-08-26","lastUpdate":"2018-02-15"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B","Hepatitis A"],"interventions":[{"type":"BIOLOGICAL","name":"Twinrixâ„¢ adult","otherNames":[]}],"arms":[{"label":"Twinrix Group","type":"EXPERIMENTAL"}],"summary":"The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 11, 12, 13, 14 and 15 years after subjects received their first dose of a 3 dose vaccination schedule of combined hepatitis A/hepatitis B vaccine. The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.\n\nThis protocol posting deals with objectives \\& outcome measures of the extension phase at year 11 to 15.","primaryOutcome":{"measure":"Anti-hepatitis A Virus (Anti-HAV) Antibody Concentration","timeFrame":"At Years 11, 12, 13, 14, and 15 after the first vaccine dose of the 3-dose primary vaccination","effectByArm":[{"arm":"Twinrix Group","deltaMin":369.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Belgium"]},"refs":{"pmids":["11505437","22052690","17448944"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":1},"commonTop":["Pain","Nasopharyngitis"]}}